Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine

Ertürk, Murat; Hill, Terry; Shimeld, C.; Jennings, R.

doi:10.1007/bf01309630

Cited by 25 publications

(13 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence for the latter was also provided in the immunized mice by the significantly lower incidence of latent infection in the sensory ganglia that supply the cutaneous inoculation site. Again, these results on latency and zosteriform spread parallel those obtained following cutaneous challenge after subcutaneous immunization with an ISCOM-based HSV-1 vaccine (Erturk et al, 1992).…”

Section: Discussionsupporting

confidence: 73%

“…Similar increased rates of clearance were also observed in mice immunized with an immunestimulating complex (ISCOM)-based HSV-1 vaccine (Erturk et aL, 1992). Since the cornea is avascular and richly innervated, after corneal scarification virus may rapidly gain access to susceptible cells and thereby to the nervous system before an immune response can be effective.…”

Section: Discussionmentioning

confidence: 61%

See 1 more Smart Citation

Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus

Irie

Shimeld²,

Williams

et al. 1993

Journal of General Virology

Self Cite

View full text Add to dashboard Cite

Intragastric administration of live herpes simplex virus type 1 (HSV-1) was assessed for the induction of humoral immune responses and for protection against ocular and cutaneous challenge with virus. Mice showed no clinical abnormalities following intragastric inoculation with three different strains of virus (Miyama +GC, SC16, and P2C6, a thymidine kinase-defective mutant). Replication of virus was not detected in the oesophagus, superior cervical ganglia or coeliac ganglia of such animals and latent infection was not detected in these ganglia at later times after inoculation. Induction of a mucosal immune response was indicated by the presence of antibody (mainly IgG or IgA)-secreting cells in Peyer's patches. Intragastric immunization gave protection to some extent against ocular challenge and to a greater extent against cutaneous challenge with HSV-1. Following the latter challenge, particularly after intragastric immunization with strains SC16 and Miyama, the establishment of latency was almost completely prevented.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 61%

Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus

Irie

Shimeld²,

Williams

et al. 1993

Journal of General Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sera were analyzed for the presence of HSV-1-specific antibodies, as described previously (7). Briefly, assay plates coated with rabbit anti-HSV-1 (Dako, Ltd., High Wycombe, United Kingdom) were incubated with 1% bovine serum albumin in PBS, followed by HSV-1 antigen, mouse serum, and a rabbit anti-mouse Ig-horseradish peroxidase (HRP) conjugate (Dako Ltd.), with O-phenylenediamine (Sigma) as a substrate.…”

Section: Methodsmentioning

confidence: 99%

Protection against Recurrent Ocular Herpes Simplex Virus Type 1 Disease after Therapeutic Vaccination of Latently Infected Mice

Richards

Case

Hirst

et al. 2003

J Virol

Self Cite

View full text Add to dashboard Cite

The potential of therapeutic vaccination of animals latently infected with herpes simplex virus type 1 (HSV-1) to enhance protective immunity to the virus and thereby reduce the incidence and severity of recurrent ocular disease was assessed in a mouse model. Mice latently infected with HSV-1 were vaccinated intranasally with a mixture of HSV-1 glycoproteins and recombinant Escherichia coli heat-labile enterotoxin B subunit (rEtxB) as an adjuvant. The systemic immune response induced was characterized by high levels of virusspecific immunoglobulin G1 (IgG1) in serum and very low levels of IgG2a. Mucosal immunity was demonstrated by high levels of IgA in eye and vaginal secretions. Proliferating T cells from lymph nodes of vaccinated animals produced higher levels of interleukin-10 (IL-10) than were produced by such cells from mockvaccinated animals. This profile suggests that vaccination of latently infected mice modulates the Th1-dominated proinflammatory response usually induced upon infection. After reactivation of latent virus by UV irradiation, vaccinated mice showed reduced viral shedding in tears as well as a reduction in the incidence of recurrent herpetic corneal epithelial disease and stromal disease compared with mock-vaccinated mice. Moreover, vaccinated mice developing recurrent ocular disease showed less severe signs and a quicker recovery rate. Spread of virus to other areas close to the eye, such as the eyelid, was also significantly reduced. Encephalitis occurred in a small percentage (11%) of mock-vaccinated mice, but vaccinated animals were completely protected from such disease. The possible immune mechanisms involved in protection against recurrent ocular herpetic disease in therapeutically vaccinated animals are discussed.

show abstract

“…Sera were analyzed for the presence of HSV-1-specific antibodies, as described previously (10), by use of HSV-1 antigen-coated assay plates, a rabbit anti-mouse Ig-HRP conjugate (Dako Ltd. High Wycombe, United Kingdom), and O-phenylenediamine (Sigma) as a substrate. The results obtained were assessed by comparison with a standard positive control serum collected from mice 4 weeks after systemic infection (cutaneous) with HSV-1 SC16, using weighted Probit analysis (3).…”

Section: Methodsmentioning

confidence: 99%

Protective Mucosal Immunity to Ocular Herpes Simplex Virus Type 1 Infection in Mice by UsingEscherichia coliHeat-Labile Enterotoxin B Subunit as an Adjuvant

Richards

Aman

Hirst

et al. 2001

J Virol

Self Cite

View full text Add to dashboard Cite

The potential of nontoxic recombinant B subunits of cholera toxin (rCtxB) and its close relative Escherichia coli heat-labile enterotoxin (rEtxB) to act as mucosal adjuvants for intranasal immunization with herpes simplex virus type 1 (HSV-1) glycoproteins was assessed. Doses of 10 g of rEtxB or above with 10 g of HSV-1 glycoproteins elicited high serum and mucosal anti-HSV-1 titers comparable with that obtained using CtxB (10 g) with a trace (0.5 g) of whole toxin (Ctx-CtxB). By contrast, doses of rCtxB up to 100 g elicited only meager anti-HSV-1 responses. As for Ctx-CtxB, rEtxB resulted in a Th2-biased immune response with high immunoglobulin G1 (IgG1)/IgG2a antibody ratios and production of interleukin 4 (IL-4) and IL-10 as well as gamma interferon by proliferating T cells. The protective efficacy of the immune response induced using rEtxB as an adjuvant was assessed following ocular challenge of immunized and mock-immunized mice. Epithelial disease was observed in both groups, but the immunized mice recovered by day 6 whereas mock-immunized mice developed more severe corneal disease leading to stromal keratitis. In addition, a significant reduction in the incidence of lid disease and zosteriform spread was observed in immunized animals and there was no encephalitis compared with 95% encephalitis in mock-immunized mice. The potential of such mucosal adjuvants for use in human vaccines against pathogens such as HSV-1 is discussed.

show abstract

Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine

Cited by 25 publications

References 46 publications

Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus

Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus

Protection against Recurrent Ocular Herpes Simplex Virus Type 1 Disease after Therapeutic Vaccination of Latently Infected Mice

Protective Mucosal Immunity to Ocular Herpes Simplex Virus Type 1 Infection in Mice by UsingEscherichia coliHeat-Labile Enterotoxin B Subunit as an Adjuvant

Contact Info

Product

Resources

About